Lonza is confident that U.S. and Swiss plants it is building to help make Moderna's COVID-19 vaccine candidate will be ready for commercial production this year, executives at the Swiss company said on Tuesday.
VISP, Switzerland - Lonza is confident that U.S. and Swiss plants it is building to help make Moderna’s COVID-19 vaccine candidate will be ready for commercial production this year, executives at the Swiss company said on Tuesday.
There is no approved COVID-19 vaccine yet, but several are in advanced trials, including from Pfizer Inc, Johnson & Johnson and Moderna, whose candidate relies on technology never previously approved that enlists human cells to help trigger an immune response. Lonza, whose shares are up 60% this year, has a 10-year contract to supply ingredients to Moderna, including for up to 1 billion doses annually of COVID-19 vaccine.
However ready Lonza is, when precisely Moderna’s vaccine becomes available depends on its trials and regulators. The U.S. company has said about 20 million doses should be ready by the year’s end.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Lonza confident of 2020 target for Moderna COVID-19 vaccine supplyLonza is confident that U.S. and Swiss plants it is building to help make Moderna's COVID-19 vaccine candidate will be ready for commercial production this year, executives at the Swiss company said on Tuesday.
Weiterlesen »
How Trump And COVID-19 Have Reshaped The Modern Militia MovementIn the video, the host of a local independent news radio program surveys the late-night shadows of a Kenosha, Wisconsin, car lot. You can just make out four men…
Weiterlesen »
Lonza confident of 2020 target for Moderna COVID-19 vaccine supplyLonza is confident that U.S. and Swiss plants it is building to help make Moderna's COVID-19 vaccine candidate will be ready for commercial production this year, executives at the Swiss company said on Tuesday.
Weiterlesen »
GlaxoSmithKline CEO optimistic COVID-19 vaccine widely available in 2021The chief executive of GlaxoSmithKline, the world's largest maker of vaccines, said she was optimistic the industry will be able to make an immunisation against COVID-19 widely available next year.
Weiterlesen »
Russian scientist behind COVID-19 vaccine defends 'wartime' roll-outRussia plans to share preliminary results of its COVID-19 vaccine trial based on the first six weeks of monitoring participants, raising the tempo in an already frenzied global race to end the pandemic.
Weiterlesen »
Russia's Putin, Japan's Suga discuss possible cooperation on COVID-19 vaccines: KremlinRussian President Vladimir Putin and Japanese Prime Minister Yoshihide Suga on Tuesday discussed possible medical cooperation, including on the development of COVID-19 vaccines, the Kremlin said in a statement.
Weiterlesen »